A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia
J. Clin. Invest. Björn de Rijke, et al. 115:3506 doi:10.1172/JCI24832 [Go to this article.]

Figure 6
P2X5 gene expression is restricted to leukemic and normal CD34⁺ progenitor cells as well as lymphoid cells. (A) P2X5 expression determined by real-time quantitative PCR in CD34⁺ subpopulations isolated from leukemia patients (CML blast crises, n = 4 and acute myeloid leukemia, n = 10) and healthy stem cell donors (normal BM, n = 4 and G-CSF–mobilized peripheral blood, n = 5). Leukemic CD34⁺ subsets isolated from CML patient UPN389 at first relapse are indicated by the arrows. (B) P2X5 expression determined by real-time quantitative RT-PCR in freshly isolated cells or primary cell cultures of hematopoietic and nonhematopoietic origin. Expression is shown relative to the P2X5 expression measured in the reference cell line JVM-2, which is susceptible to lysis by the LRH-1–specific CTL RP1. The housekeeping Pbgd gene was used for normalization. Cell types with P2X5 expression less than 0.4 were not recognized by CTL RP1, indicating that these cell types can be considered as LRH-1 negative. This arbitrary threshold is indicated with a dashed line. The mean expression level for each cell population is shown by the thick line.